Search results
Results from the WOW.Com Content Network
Phototherapy is the main treatment of neonatal jaundice. Babies with neonatal jaundice may be treated with colored light called phototherapy, which works by changing trans-bilirubin into the water-soluble cis-bilirubin isomer. [26] [27] [28]: 2533
If neonatal cholestasis is suspected or an infant is presenting with jaundice after two weeks of life, total and conjugated bilirubin must be measured. [10] Neonatal cholestasis is present if conjugated bilirubin value is >20% of total serum bilirubin or if serum conjugated bilirubin concentration is greater than 1.0 mg/dL. [2]
[citation needed] Diagnosis is usually made by investigation of a newborn baby who has developed jaundice during the first week of life. Testing. Coombs - after birth, the newborn will have a direct Coombs test run to confirm antibodies attached to the infant's red blood cells. This test is run from cord blood. [5]
Traditional phototherapy devices include blue LEDs, halogen white light, and fluorescent tubes. A biliblanket is a phototherapy home treatment that consists of a portable illuminator and fiber-optic pad. It uses a pad of woven fibers to transfer light to a baby in order to treat neonatal jaundice (hyperbilirubimia).
It has also been found that tin mesoporphyrin can aid in the prevention of neonatal jaundice. When administered to pre-discharge newborns who were at risk for neonatal jaundice the results showed a decrease in total biliverdin load, the possibility of postnatal bilirubin progression, as well as the use and duration of phototherapy. [11]
Treatment of the condition is specific to the cause of hemolysis, but intense phototherapy and exchange transfusion can be used to help the patient excrete accumulated bilirubin. [11] Complications related to hemolytic jaundice include hyperbilirubinemia and chronic bilirubin encephalopathy, which may be deadly without proper treatment. [12] [13]
Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis fetalis, [1] [2] is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules (one of the five main types of antibodies) produced by the mother pass through the placenta.
In industrialized countries, treatment for neonatal infections takes place in the neonatal intensive care unit (NICU). Neonatal infection can be distressing to the family and it initiates concentrated effort to treat it by clinicians. Research to improve treatment of infections and prophylactic treatment of the mother to avoid infections of the ...